secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001193125-23-002528
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus extends $25M second tranche draw to March 2024, reduces interest rate on credit facility
--------------------------------------------------------------------------------

- Second tranche of $25M under loan agreement: draw period extended to March 15, 2024; minimum $5M drawn by March 15, 2023 and another $5M by Sept 15, 2023.
- Third tranche of $35M available upon FDA approval of TP-03 for Demodex blepharitis; must be drawn by March 15, 2024.
- First tranche balance of $20M expired undrawn on December 15, 2022.
- Interest rate reduced to prime plus 4.45% (cap 11.45%) or floor 8.45%; no lender fees incurred.
- Regulatory milestone for second tranche draw already achieved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000119312523002528/0001193125-23-002528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000119312523002528/d427625d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-002528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer